Next Article in Journal
Early Warning of Internal Leakage in Heat Exchanger Network Based on Dynamic Mechanism Model and Long Short-Term Memory Method
Next Article in Special Issue
PPO-Inhibiting Herbicides and Structurally Relevant Schiff Bases: Evaluation of Inhibitory Activities against Human Protoporphyrinogen Oxidase
Previous Article in Journal
Chromatographic and Computational Screening of Lipophilicity and Pharmacokinetics of Newly Synthesized Betulin-1,4-quinone Hybrids
Previous Article in Special Issue
In Vitro Molecular Biology Studies of Spirooxindole Heterocyclic Hybrids

Evolution of Nitrogen-Based Alkylating Anticancer Agents

Oncopeptides AB, Västra Trädgårdsgatan 15, SE-111 53 Stockholm, Sweden
Red Glead Discovery AB, Scheeletorget 1, 223 63 Lund, Sweden
Author to whom correspondence should be addressed.
Academic Editors: Zdenek Kejik and Michal Masarik
Processes 2021, 9(2), 377;
Received: 20 January 2021 / Revised: 10 February 2021 / Accepted: 12 February 2021 / Published: 19 February 2021
(This article belongs to the Special Issue Advances in Anticancer Agents)
Despite the significant progress in anticancer drug development over recent years, there is a vital need for newer agents with unique, but still effective, mechanisms of action in order to treat the disease, particularly the highly aggressive and drug-resistant types. Alkylating agents, in particular nitrogen-based alkylators, are commonly used to treat hematological and solid malignancies; they exert their antineoplastic effects at all phases of the cell cycle and prevent reproduction of tumor cells. Certain alkylating agents have been designed to be more lipophilic, enabling the compound to penetrate the cell and enhance its alkylating activity against tumors. This review details the evolution of currently available alkylating agents and their profiles, with a focus on nitrogen-based alkylating agents, as important anticancer therapy strategies. View Full-Text
Keywords: alkylating agents; alkylators; antineoplastic agents; cytotoxicity; lipophilicity; nitrogen mustard alkylating agents; alkylators; antineoplastic agents; cytotoxicity; lipophilicity; nitrogen mustard
Show Figures

Figure 1

MDPI and ACS Style

Lehmann, F.; Wennerberg, J. Evolution of Nitrogen-Based Alkylating Anticancer Agents. Processes 2021, 9, 377.

AMA Style

Lehmann F, Wennerberg J. Evolution of Nitrogen-Based Alkylating Anticancer Agents. Processes. 2021; 9(2):377.

Chicago/Turabian Style

Lehmann, Fredrik, and Johan Wennerberg. 2021. "Evolution of Nitrogen-Based Alkylating Anticancer Agents" Processes 9, no. 2: 377.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop